Heart Health Biotech Kardigan Up 27% After $400 Million IPO

Kardigan, a biotech company focused on cardiovascular diseases, successfully completed an upsized initial public offering (IPO) on June 17, 2026, raising $400 million. The company priced 25,000,000 shares of common stock at $16 per share, which was at the top end of its anticipated range of $14.00 to $16.00. This IPO extends a recent trend of large biotech IPOs, marking Kardigan as the fourth drug startup in 2026 to raise at least $400 million.

Following its Nasdaq debut on June 18, 2026, under the ticker symbol "KARD," Kardigan's stock surged immediately. Shares climbed by 27% above the IPO price, indicating strong investor confidence in the company's prospects. At the time of its pricing, Kardigan commanded a market capitalization of $1.43 billion.

Kardigan is developing three clinical-stage cardiovascular drugs. Its lead drug, danicamtiv, was originally discovered by MyoKardia, a company acquired by Bristol Myers Squibb. Kardigan licensed danicamtiv from Bristol Myers in 2024 and is developing it for genetically driven dilated cardiomyopathy, a condition with no approved treatments. Earlier studies suggest danicamtiv could improve heart function, with Phase 2b/3 trial data expected in the first half of 2027. The company's pipeline also includes a potential treatment for acute severe hypertension, tonlamarsen, with initial Phase 2 data expected in 2027. J.P. Morgan, Jefferies, Leerink Partners, and T.D. Cowen led the joint book-running team for the IPO.

Kardigan was founded by former MyoKardia executives and unveiled itself in January 2025. Prior to its IPO, the company had already raised close to $600 million in private venture funding. Principal shareholders before the IPO included ARCH Venture Partners and HRTG Partners, each holding 22.4% stakes, with Perceptive Advisors at 12.7% and Fidelity Management & Research (FMR) at 6.9%. While the company has no revenue and reported a net loss of $229.99 million for the 12 months ending March 31, 2026, the successful IPO provides significant capital to advance its late-stage drug candidates.